Login
Navigate Fool.com
Will SGEN beat
the market?

Seattle Genetics

NASDAQ: SGEN

Community Rating: 3 Stars: Appealing

38.57 1.55 (4.19%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $37.25
Previous Close $37.02
Daily Range $36.80 - $39.20
52-Week Range $28.15 - $55.99
Market Cap $4.7B
P/E Ratio -72.59
Dividend (Yield) $0.00 (0.0%)
Volume 1,256,077
Average Daily Volume 1,238,410
Current FY EPS -$0.98

How do you think SGEN
will perform against the market?

Top SGEN Bull/Bear Pitches

 

irishred1 (< 20)
Submitted March 20, 2011

unique antibody drug conjugate technology with many big pharma partnerships...first candidate about to gain approval if the FDA isn't phased by the single arm trial design. I see nothing but upside l … More

0 Replies Reply Report this Post
 

PDTBiotech (< 20)
Submitted July 7, 2011

$2.34B for a drug which treats HL and ALCL seems very, very rich, even when taking SGEN's strong balance sheet into account. Very cool platform, but the target for brentuximab vedotin is expressed on … More

1 Replies Reply Report this Post

News & Commentary Rss Feed

5 Biotechs With Prostate Cancer Treatments Worth Watching

Prostate cancer is now the second leading cause of cancer-specific deaths among men in the United States. Here are five biotechs aiming to meet this challenge with a diversity of promising new therapies.

SGEN Crosses Below Key Moving Average Level

Is It Time to Buy These 2 Cancer-Fighting Companies?

Seattle Genetics' (SGEN) and Pharmacyclics' (PCYC) shares are tumbling, despite promising cancer drugs that could see significant sales growth.

Will Vintafolide Approval Silence Endocyte Bears?

See why the bearish attitude toward Endocyte was wrong, and right.

Interesting SGEN Put And Call Options For May 17th

New Stock Coverage: Home Shop Till You Drop at HSN Inc.

Wall Street ratings agencies set the tone for today's stock market.

New Stock Coverage: HSN Inc, Seattle Genetics, and Eagle Pharmaceuticals

Wall Street ratings agencies set the tone for today's stock market.

Cantor Fitzgerald Says Sell Twitter and Five Other Stocks Now

What You Need to Know About Seattle Genetics' Biggest Growth Driver

Seattle Genetics (SGEN) successful Hodgkin's lymphoma drug Adcetris has an opportunity for significant growth if ongoing trials succeed.

The Top Five Analyst Sell Ratings This Week

See More SGEN News...

Sector

Healthcare

Industry

Drugs

Seattle Genetics (SGEN) Description

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Website: http://www.seagen.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks